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PB1F2 is the 11th protein of the inﬂuenza A virus. The protein has variable sizes with truncations either
at the C- or N-terminal ends. The most recent example being the 2009 pandemic H1N1 virus which
codes for only 11 amino-acids of the C-terminus. A review of the reports since the discovery of PB1F2
in 2001 suggests a multifunctional role for this protein that includes a proapoptotic function in immune
cells and an ability to cause increased pathogenesis in animal models by dysregulating cytokines and
inducing inﬂammation. It has also been suggested that PB1F2 regulates polymerase activity via
co-localization with PB1 and causes enhanced secondary bacterial pneumonia. This review primarily
focuses on understanding the proapoptotic ability of PB1F2, its sub-cellular localization and the
mechanism through which it brings about apoptosis. We believe there is much more to learn about
PB1F2, as many of its proposed functions are strain, host or cell-line speciﬁc.
& 2013 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza is an important and pathogenic viral disease infect-
ing warm-blooded animals. This virus continuously evolves, thus
causing the emergence of newer epidemics and pandemics in
human swine, horses, dogs, cats, and other mammals. Aquatic
birds are the natural reservoir for all the subtypes of inﬂuenza A
virus and are most likely the deﬁnitive source of human pandemic
inﬂuenza strains (Webster et al., 1992). Since 1500, there have
been 14 or more inﬂuenza pandemics. In the past 133 years,
during the so-called microbial era from 1876 to the present, there
have been six pandemics. Those pandemics include the ﬂu
pandemics of 1889, 1918, 1957, 1968, and 1977, and the recent
2009 pandemic (Taubenberger et al., 2010). Compared to the
pandemic inﬂuenza A strains, H5N1 viruses are more pathogenic
and cause higher mortality, although they are not transmitted
from human to human. Widespread and ongoing epizootic out-
breaks of H5N1 viruses in Asia have increased the concern that
this subtype may achieve human-to-human transmission and
establish interspecies spread. Many transmission events involving
H5N1 viruses to humans have been reported since 1997 (Lipatov
et al., 2004). From 2003 until June 2012, six hundred and six cases
of H5N1 human infection have been reported, of which 357 were
fatal. To date, H5N1 has been reported in 15 countries. Accordingll rights reserved.
arti).to data available from up to June 2012, most cases of human
infections with H5N1 virus have been reported in Indonesia and
Egypt (WHO data, 2012).
Continuing evolution is most prominent in the surface glyco-
proteins of inﬂuenza viruses, but it also occurs in each of the eight
gene segments of the virus. Among the eight segments, PB1 is of
particular interest, as the PB1 gene is the only other segment that
was exchanged in the pandemic viruses of 1957 and 1968
(Kawaoka et al., 1989). In addition, a novel PB1 gene was found
in the 1998 swine reassortant viruses, implicating the gene’s role
in the pathogenesis of inﬂuenza (Karasin et al., 2000). Recent
reconstruction of the 1918 virus has also conﬁrmed that the viral
polymerase is required for the pathogenicity of the recombinant
1918 virus in mice, and if it is replaced with the recent H1N1
polymerase genomic segment, the virus is attenuated in mice
(Tumpey et al., 2005). Selection of the PB1 gene in the previous
pandemic strains and its ability to enhance the pathogenicity and
virulence of the inﬂuenza A viruses warrant further study of PB1
(Kawaoka et al., 1989; Zamarin et al., 2006; Chen et al., 2001).
PB1 is encoded by segment 2 of the inﬂuenza viral genome and is
a core component of the viral polymerase. The single mRNA
transcribed from segment 2 encodes three proteins, PB1, PB1F2
and N40. PB1F2 is the second protein encoded by the þ1
alternate open reading frame within the PB1 gene. The translation
of the protein starts from the 4th initiation codon that is from
nucleotide position 120 surpassing three other initiation codons
of the PB1 gene (Chen et al., 2001). The ﬁfth initiation codon of
segment 2 is used to initiate translation of a third protein product
Table 1
PB1F2 variants present in IAV strains H1N1, H2N2, H3N2 and H5N1 from
various hosts.
S.
no.
Strains/host No. of
analyzed
strains
101aa 90aa 87aa N57aaa C52aab Varied
size
1 H1N1 1530 – 176 42 1080 221 11
Human 1155 – 32 41 1073 6 3
Swine 261 – 43 1 7 202 8
Avian 112 – 99 – – 13 –
Environment 1 – 1 – – – –
Others 1 – 1 – – – –
2 H2N2 83 1 81 – 1 – –
Human 54 1 52 – 1 – –
Swine – – – – – – –
Avian 22 – 22 – – – –
Environment 1 – 1 – – – –
Others 6 – 6 – – – –
3 H3N2 2566 26 2105 45 – 337 53
Human 2419 25 1979 44 – 324 47
Swine 76 – 63 1 – 7 5
Avian 68 1 60 – – 6 1
Environment 2 – 2 – – – –
Others 1 – 1 – – – –
4 H5N1 919 – 886 2 4 21 6
Human 220 – 211 – 2 4 3
Swine 13 – 13 – – – –
Avian 666 – 643 2 1 17 3
Environment 16 – 15 – 1 – –
Others 4 – 4 – – – –
a Fifty-seven amino-acid fragment with C-terminal end truncated.
b Fifty-two amino-acid fragment with N-terminal truncation.
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AUG1 of the PB1, and therefore, N40 is just a truncated form
of PB1 that lacks the ﬁrst 39 amino acids of the longer protein.
N40 lacks the N-terminal region that is essential for the interac-
tion of PB1 with PA (Wise et al., 2009).There is much to learn
about the three translation products of PB1 mRNA, and it is
believed that the three proteins are dependent on each other for
their functions. Given the last outbreak scenario, wherein the
emergence of the 2009 H1N1 inﬂuenza virus took public-health
authorities by surprise, it is essential to gather in-depth knowl-
edge about each of the viral proteins of the inﬂuenza A virus.
There is a dearth of knowledge about and treatments for inﬂu-
enza. Thus, researchers need to develop effective vaccines and
therapies, in addition to predicting newly emerging pandemic
inﬂuenza viruses.
PB1F2 is a non-structural protein of the inﬂuenza A virus that
was identiﬁed and characterized more than a decade ago by Chen
et al. (2001). It was discovered in the A/PuertoRico/8/34 (H1N1)
strain while screening for a antigenic peptides recognized by CD8þ
T lymphocytes (Chen et al., 2001). The PB1 gene has inefﬁcient
initiation of translation, as it does not possess a consensus Kozak
sequence in that it does not have a purine nucleotide in the 3
position of the ORF. The fourth initiation codon is surrounded by an
exact Kozak sequence and allows for the synthesis of PB1F2 (Kosˇı´k
et al., 2011). PB1F2 is absent in inﬂuenza B viruses. PB1F2 is
exclusively expressed in infected cells with maximum expression
at 5 h post-infection and is possibly not incorporated into the
virion (Krumbholz et al., 2011). Many of the inﬂuenza A virus
strains encode a full-length PB1F2 protein with 90 or 87 amino
acids and a molecular weight of 10.5 kDa.
Structure of PB1F2
Chen et al. described that the novel PB1F2 has a propensity to
form an amphipathic helix extending from the 69th amino acid
(Leucine) to the 83rd amino acid (Phenyalanine) of the protein
(Chen et al., 2001). Detailed study of the protein revealed that
PB1F2 consists of two independent structural domains consisting
of two close short helices at the N-terminus and an extended
helix at the C-terminus. Both helical domains are connected by a
ﬂexible and unstructured hinge region (Bruns et al., 2007).
The PB1F2 molecule has an intrinsic strong propensity to form
oligomeric structures, a characteristic that supports the recent
observation that the molecule can form membrane pores in
planar lipid bilayers (Bruns et al., 2007; Henklein et al., 2005).
The major oligomerization domain is located in the C-terminal
helix (Bruns et al., 2007). In another study, PB1F2 was determined
to belong to a group of intrinsically disordered proteins that can
switch their conformation from a random to a-helical or b-sheet
secondary structure depending on the environment. PB1F2 has
also been reported to permeabilize cellular membranes; however,
this ability is dependent on the amino acid sequence of the
inﬂuenza A virus strain. The PB1F2 protein has also been shown
to oligomerize and form amyloid ﬁbers in infected cells. Amyloid
ﬁber formation in the infected cells could give insight into the
pathogenicity of the virus and also into the relationship of the
inﬂuenza virus with nervous system disorders (Chevalier et al.,
2010). PB1F2 has also been reported to be a phosphoprotein,
wherein its function is regulated by protein kinase C (PKC).
PKC phosphorylation sites have been mapped to amino acid
positions 27 and 35 of the PB1F2 protein (Mitzner et al., 2009).
Varying length of PB1F2 protein
Varying sizes of the PB1F2 protein have been reported in
different subtypes of inﬂuenza A viruses. A comprehensiveanalysis of the varying lengths of the PB1F2 protein from 20th-
century pandemics and H5N1 subtypes was previously conducted
by our group (Pasricha et al., 2012). The 1918 H1N1 virus
responsible for the Spanish ﬂu harbored a complete PB1F2 protein
(McAuley et al., 2007). However, since 1949, most H1N1 virus
strains have an incomplete PB1F2 protein with truncation either
at the N- or C-terminal end (Zell et al., 2007; Pasricha et al., 2012).
The N-terminal end of the protein is preserved in human hosts,
while the C-terminal end is retained in swine (Table 1). Interest-
ingly, the recent 2009 pandemic H1N1 virus harbors only an 11
amino acid C-terminal-truncated protein, which is thought to be
non-functional. This indicates that this protein is not essential for
the ﬁtness of the H1N1 strain. The H2N2 subtype responsible for
the 1957 pandemic (Asian ﬂu) infected close to 250,000 people.
Analysis of the 83 available PB1F2 sequences belonging to the
H2N2 subtype revealed that 98.8% of the strains harbored a full-
length PB1F2 protein (Table 1) and more than half of its amino
acids were conserved in the strains. The circulating strains of
H2N2 were replaced by H3N2 strains in 1968, which emerged as
new pandemic strain (Hong Kong ﬂu). The majority of the strains
(94.27%) isolated during this pandemic also harbored a full-length
PB1F2 protein (Table 1). An analysis of the length of PB1F2 protein
in H5N1 strains indicates that it is comparable to that of the H2N2
and H3N2 subtypes, wherein a complete protein is found in 96%
of the strains, suggesting that PB1F2 is positively selected in these
subtypes and is deﬁnitely essential for the virus.
Cellular and humoral response to the PB1F2 protein
The PB1F2 protein is recognized by the human immune
system and therefore has the ability to elicit both humoral and
cell-mediated immune responses. The discovery of PB1F2 was
based on its ability to generate a robust CD8þT cell response
speciﬁc for a well-deﬁned peptide encoded by residues 62-70
(LSLRNPILV) of the protein (Chen et al., 2001; La Gruta et al.,
2008). PB1F2-speciﬁc antibodies have been detected in the sera of
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human acute and convalescent sera collected during the H3N2
2003–2004 epidemic. This result provides evidence that PB1F2
is recognized by the immune system and can elicit an adaptive
immune response, although only for a short duration (Krejnusova´
et al., 2009). Khurana et al. (2009) also detected antibodies
against PB1F2 in the sera of convalescent patients recovering
from the H5N1 infection caused by A/Vietnam/1203/2004 in
Vietnam.Multifunctional role of PB1F2 protein
Five main functions of the PB1F2 protein have been found:
(i) direct or indirect role in apoptosis of the immune cells via
mitochondrial pathway, (ii) exacerbation of pathogenicity in animal
models, (iii) modulator of innate immune response in host cells both
in vitro and in vivo model, (iv) regulation of polymerase activity byFig. 1. Multifunctional role of PB1F2 protein.
Fig. 2. Different mechanisms by which PB1F2 protein brinco-localization with PB1 and (v) enhancement of secondary bacterial
pneumonia (Fig. 1).
Proapoptotic function of PB1F2
PB1F2 is a small protein that has an intrinsic property to
localize to mitochondria and cause alterations in its morphology
that ultimate dissipate the mitochondrial membrane potential,
which induces apoptosis (Chen et al., 2001). Chen et al. (2001)
demonstrated that the apoptosis was more pronounced in
immune cells (macrophages), thus reducing the ability of the
host to contribute to an immune response. Among the various
apoptotic agents produced by inﬂuenza A viruses, PB1F2 is the
only inﬂuenza viral protein that intrinsically localizes and inter-
acts with the mitochondrial-dependent apoptotic pathway (Lowy,
2003).Mechanism by which PB1F2 protein brings about apoptosis
The PB1F2 protein has a short mitochondrial targeting
sequence (MTS, 65–87aa) at the C-terminus of the protein that
is thought to be essential for inner mitochondrial membrane
localization and subsequent apoptosis (Gibbs et al., 2003).
Fine mapping and mutational analysis of the putative MTS of
the PB1F2 protein revealed that the presence of a double leucine
residue in the MTS is very crucial. Leucine forms a hydrophobic
groove in the PB1F2 protein that, in turn, interacts with the TOM
(transporter outer membrane) receptor. This interaction facili-
tates translocation of PB1F2 a helix through the IMM (inner
mitochondrial membrane) and OMM (outer mitochondrial mem-
brane), resulting in a loss of MMP (mitochondrial membrane
potential) and the initiation of apoptosis (Gibbs et al., 2003)
(Fig. 2). However, in another study, amino acid residues fromgs about depolarization of mitochondrial membrane.
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which Lys73 and Arg75 were minimally required for a functional
MTS (Yamada et al., 2004) (Fig. 2). The PB1F2 protein was shown
to arrest the cell cycle in the ‘S’ or ‘Synthesis’ phase. In the
S phase, the mitochondria are fragmented, hence altered mor-
phology results in the loss of MMP and subsequent apoptosis
(Yamada et al., 2004) (Fig. 2). Chanturiya et al. (2004) worked
with synthetic PB1F2 proteins and described the protein’s inter-
action with lipid head group charges and a transmembrane IMM
electric ﬁeld. This interaction leads to the incorporation of PB1F2
in the mitochondrial membrane and formation of potential-
dependent lipidic pores. These pores depolarize the mitochondrial
membrane, causing an increase in the conductance of the planar
lipid bilayers, subsequent breakdown of the bilayers and ﬁnally
apoptosis (Fig. 2). However, in another study, PB1F2 was shown
to have the ability to form non-selective protein-mediated pores
in planar lipid membranes. These non-selective water-ﬁlled
protein pores are formed by the oligomerization or self-
assembly of PB1F2 monomers in the mitochondrial membrane.
These pores disrupt the reticulotubular mitochondrial organiza-
tion and damage the inner membrane of the mitochondria and
bring about apoptosis (Henkel et al.,2010). The C-terminal domain
(amino acid residues Ile55-Lys85), which forms an a-helical
structure, was found to be stable and was thought to be mainly
involved in the formation of these protein channels. Despite the
sequence variability between H1N1 and H5N1 virus, non-
selective protein channels and similar apoptotic changes were
observed in both (Henkel et al.,2010) (Fig. 2). In continuing to
unravel the mechanism by which PB1F2 compromises the mito-
chondrial membrane and brings about apoptosis, Zamarin et al.
(2005) demonstrated that PB1F2 indirectly interacts with the
mitochondrial membrane through the mitochondrial transport
proteins ANT3 (Adenine nucleotide translocator 3) and VDAC1
(voltage-dependent anion channel 1), present on the inner and
outer mitochondrial membrane, respectively. The C-terminal
domain of the PB1F2 protein interacts with ANT3, while both
the N- and C-terminal regions are essential for its interaction with
VDAC1. Both the mitochondrial membranes and PB1F2 form
permeability transition pore complexes (PTPCs), which play a
role in the permeabilization of the mitochondria and inducing cell
death (Fig. 2) (Zamarin et al., 2005). Another study used an in
silico approach to understand the interaction between the
C-terminal end of the PB1F2 protein of a highly pathogenic
inﬂuenza A H5N1 strain and the two mitochondrial proteins
VDAC1 and ANT3. The study revealed that 22 amino acids of the
VDAC1 protein make hydrophobic contacts with the 12 amino
acids of the C-terminal end of the protein. Of these amino acids,
Leu64, Arg75 and Val76 are the most important for mitochondrial
targeting. In addition, 14 amino acids of ANT3 make hydrophobic
contacts with 9 amino acids present on the C-terminal end of the
PB1F2 protein (Danishuddin et al., 2010).Cell type and virus strain-speciﬁc proapoptotic role of PB1F2
Chen et al. (2001) showed that apoptosis was more pro-
nounced in immune cells than in epithelial cells. McAuley et al.
(2010) studied PB1F2 proteins from pandemic strains from the
20th century (H1N1-1916, H2N2-1957; H3N2-1968), a HPAI virus
of the H5N1 subtype, H1N1 PR8 and representative seasonal
strains and demonstrated that only the laboratory strain A/Puerto
Rico/8/34 (H1N1; PR8) had the ability to cause apoptosis in both
epithelial and immune cell lines. Hence, it was deduced that the
ability to cause cell death is virus-strain speciﬁc, and apoptosis
is not a likely contributor to pathogenicity in humans. In the
PR8 strains, cell death is achieved through the interaction of the
PB1F2 protein with BAK/BAX and mediated through the release ofcytochrome c from mitochondria (McAuley et al., 2010).
In another study, the PB1F2 protein of an H5N1 strain (A/Hong
Kong/156/1997) did not localize to mitochondria and also did
not demonstrate proapoptotic potential (Chen et al., 2010).
The researchers attributed this result to the lack of leucine-rich
amino acids in the mitochondrial target sequence (MTS), which
are essential for apoptosis (Gibbs et al., 2003). However, when
they created recombinant PB1F2 H5N1 virus with double leucine
mutations at positions 69 and 75, the virus localized to the
mitochondria. This result emphasizes the importance of leucine
in the MTS (Chen et al., 2010).
Contribution of the PB1F2 protein in exacerbating pathogenicity
in animal models
The PB1F2 protein has been determined to exacerbate patho-
genicity in mammalian and avian hosts. It has been hypothesized
that PB1F2 increases pathogenicity in mice mainly by delaying
the clearance of the virus by the host immune system. It is
speculated that the delay is due to apoptosis of the antigen-
presenting cells, such as macrophages and dendritic cells, which
are responsible for clearance (Zamarin et al., 2006). PB1F2 has
been shown to increase pathogenicity in recombinant Spanish ﬂu
virus (r1918) infected mice by elevating the cell death responses
of the host (Kash et al., 2006). A PB1F2 protein with an N66S
mutation contributes to the pathogenicity of the highly patho-
genic H5N1 and 1918 Spanish ﬂu H1N1 viruses. The above viruses
cause increased morbidity and mortality in mice (Conenello et al.,
2007). An N66S (arginine to serine) mutation is present in the
C-terminal region of the PB1F2 protein. That position is part of the
a-helical region and is in the MTS of the PB1F2 protein, which is
proposed to be essential for the apoptotic function of the protein.
This mutation was reported ﬁrst in the H1N1 inﬂuenza A virus
responsible for the 1918 Spanish ﬂu and in the highly pathogenic
H5N1 virus of the 1997 Hong Kong outbreak (Conenello et al.,
2007). The exacerbated pathogenicity is mainly due to increased
viral titers and elevated levels of IFNg and TNFa in infected mouse
lungs (Conenello et al., 2007). The N66S mutation contributed to
the viral pathogenicity of the 1918 pandemic virus in mice and
causes both primary viral as well as secondary bacterial infection
(McAuley et al., 2007). Comparison of the in vivo kinetics of the
PR8 inﬂuenza strain and its recombinant counterpart, rPR8, with
PB1F2 from the 1918 inﬂuenza virus revealed that rPR8 resulted
in a higher rate of viral production and cell death and hence, the
virus strain was more pathogenic. Using mathematical equations
and data from previous reports (McAuley et al., 2007; Mohler
et al., 2005), it was suggested that the burst size of the rPR8
inﬂuenza virus-infected cells was much higher than that of
its wild-type counterpart, which may mimic the effect of
PB1F2 on the infection dynamics of the 1918 H1N1 virus (Smith
et al., 2011).
The contribution of PB1F2 to enhancing the pathogenicity of
the 1918 pandemic H1N1 virus is undoubted. In contrast, inter-
estingly, this protein is present in a truncated form in the H1N1
2009 pandemic virus, which leads to a questioning of the func-
tional utility of this protein in inﬂuenza viruses in human hosts.
The PB1F2 protein of the H1N1 2009 pandemic differs from its
recent ancestors by harboring a point mutation (C129A) in the
PB1 gene that leads to the formation of a stop codon in place of
serine. The result of which is the transcription of a truncated 11
amino acid protein. Apart from the stop codon at the 12th amino
acid position, it harbors another two stop codons at positions 58
and 88 (Smith et al., 2009). To understand the contribution of
PB1F2 to the recent 2009 H1N1 pandemic strain, Hai et al. (2010)
generated recombinant viruses expressing full-length PB1F2
containing either an asparagine or serine at position 66 in the
Table 2
Strains of the H1N1, H2N2, H3N2 and H5N1 subtypes with an N66S mutation in
the PB1F2 protein from various hosts.
Subtype Host Total no.
of strains
No. of strains
harboring mutation (%)
H1N1 1530 100 (6.5)
Human 1155 0
Avian 112 91 (81.25)
Swine 261 7 (2.68)
Environment 1 1 (100)
Others 1 1 (100)
H2N2 83 24 (28.9)
Human 54 2 (3.7)
Avian 22 16 (72.7)
Environment 1 1 (100)
Guinea pig 6 5 (83.3)
H3N2 2566 89 (3.96)
Human 2419 30 (1.2)
Avian 68 53 (77.9)
Swine 76 3 (3.9)
Environment 16 2 (12.5)
Dog 1 1 (100)
H5N1 919 35 (3.8%)
Human 220 6 (2.7)
Avian 666 17 (2.5)
Environment 16 12 (70.5)
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04/2009. They performed both in vitro and in vivo infection assays
and found increased replication of the N66S virus in A549 cells,
while no signiﬁcant changes were observed in mice and ferrets.
The co-infection of mice with these viruses and Streptococcus
pneumoniae resulted in insigniﬁcant changes in the mortality of
BALB/c or DBA/2 mice. The only difference the researchers
observed was in modulation of the immune system in the mice,
wherein there was an increased proinﬂammatory response in the
mice with the virus with the N66S mutation in the full-length
PB1F2. The ﬁndings that full-length PB1F2 in pandemic strain
A/California/04/2009 did not signiﬁcantly alter both primary viral
infection or the secondary bacterial infection with S. pneumoniae
intrigued the authors, and they concluded that PB1F2 most likely
enhances the virulence of the virus in as strain-speciﬁc manner
(Hai et al., 2010). In continuing to unravel the mystery of the
presence of the truncated PB1F2 in the 2009 pandemic strain,
Chen et al. created a recombinant pandemic 2009 H1N1 virus
strain with a complete PB1F2 fragment and found enhanced viral
replication that resulted in high viral titers. The viral titer peaked
unusually earlier than in the wild-type virus at 24 h. High viral
titers caused the death of host cells, thus preventing newer
viruses from continuing further replication. Chen et al. (2010)
speculated this could be one of the many reasons why the
pandemic H1N1 strain lacked full-length PB1F2 protein.
PB1F2 contributed to the pathogenicity of A/Vietnam/1203/04
(H5N1; VN1203) in mallard ducks. Three synonymous mutations
inadvertently introduced into the PB1 gene caused substitutions
at position 51, 56 and 87 of the PB1F2 gene of the reverse
genetics-derived rgVN1203 virus, which reduced the lethality in
mallard ducks (Marjuki et al., 2010). The potential of the PB1F2
protein (with and without the N66S mutation) to exacerbate viral
pathogenicity was further explored and compared in both mam-
malian and avian hosts by Schmolke et al. (2011) HPAI (VN1203)
virus with the PB1F2 protein harboring an N66S mutation, when
inoculated into the mice, lead to increased replication of the virus,
although a virus with a knocked-out PB1F2 gene presented
minimal effects on the life cycle. In contrast, in ducks, HPAI virus
with an N66S mutation played a minor role in pathogenesis, but
infection with virus with a complete deletion of the PB1F2 ORF
resulted in delayed onset of clinical symptoms and systemic
spreading of the virus. Thus, PB1F2 is an important pathogenicity
factor in ducks that is independent of sequence variations at
position 66 and is hence conserved in avian inﬂuenza strains.
In mammalian hosts, PB1F2 only impacts the pathogenicity when
the protein contains particular amino acid motifs, such as the rare
N66S polymorphism (Schmolke et al., 2011). The contribution of
PB1F2 to the pathogenesis of primary viral infection with seasonal
inﬂuenza virus (H1N1 A/USSR/90/77) was studied in ferret and
macaque ex-vivo lung cultures by Meunier et al. (2012) The study
revealed that PB1F2 modulated the initial host response but did
not affect the pathogenesis of the H1N1 seasonal virus, thus
questioning the importance of PB1F2 in enhancing pathogenicity
in mammalian hosts.
In our study, we analyzed the presence of the N66S mutation
in virus strains responsible for the 20th-century pandemics and
the H5N1 subtype. The analysis revealed that this mutation was
present in only 100(6.5%) of the total 1530 H1N1 viruses studied
(Table 2). It was present in 91(81.25%) of the 112 H1N1 strains
from avian hosts and in 7 (6.2%) viruses from swine hosts;
however, none of the strains from humans harbored this muta-
tion (our analysis did not include the H1N1 strains of the Spanish
ﬂu). As of October 2011, PB1F2 sequences of only 83 strains
belonging to the H2N2 subtype were available in the global data
base, (http://www.ﬂudb.org) and among them, 24 (28.9%) of
the strains carried the N66S mutation. Among those strains,16 (72.2%) were present in the viruses derived from avian hosts
(Table 2). In our comprehensive analysis of 2566 PB1F2 sequences
from the H3N2 subtype strains, only 89 (3.96%) of the strains
were positive for the N66S mutation. Majority of the strains
(77.9%) which carried the N66S mutation were from avian hosts.
Of importance, is the presence of N66S mutation in majority of
the virus strains from avian hosts in H1N1, H2N2 and H3N2
subtypes. It would of interest to study the relevance and con-
tribution of this mutation to the pathogenicity of the virus in
these subtypes.
In addition, the analysis of 919 PB1F2 sequences belonging to
the H5N1 subtype revealed that only 35 (3.8%) of the strains
harbored the N66S mutation. The mutation was present in 6
(2.7%) of the 220 H5N1 strains from human hosts, in 17 (2.5%) of
the 660 strains from the avian hosts and in 12 (70%) of the 17
strains isolated from the environment, which are considered to
have low pathogenicity. We found that this mutation is not
present in any of the viral strains that were recently isolated
from humans from in Indonesia, Vietnam or Egypt. Therefore,
considering this mutation as a marker of high pathogenicity is
questionable in the viruses from the H5N1 type. In searching for
pathogenic markers in H5N1 viruses, we identiﬁed a mutation,
N84S, which substituted the amino acid asparagine for serine at
the 84th position of the C-terminus of the PB1F2 protein. This
mutation was present in 86 (9.35%) of the 919 H5N1 strains.
Although both the amino acids are polar, uncharged and hydro-
philic, we hypothesize that this mutation might bring about a
change in mRNA folding and the rate of protein translation, which
may bring about changes in the way the protein functions. This
mechanisms needs to be validated by both in vivo and in vitro
experiments.
PB1F2, a modulator of innate immune response
PB1F2 has been implicated in enhancing the lung inﬂamma-
tory response in mouse models. PB1F2 proteins from pandemic
strains from the 20th century, an HPAI virus of the H5N1 subtype,
H1N1 PR8 and representative seasonal strains have been shown
to cause inﬂammatory responses and increased cellularity of the
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dendritic cells, macrophages and neutrophils (McAuley et al.,
2010). It was hypothesized that either PB1F2 is directly recog-
nized by the pattern recognition receptors of the innate immune
system or it just serves as a chemoattractant (McAuley et al.,
2007). The proinﬂammatory role of PB1F2 is also thought to be
due to the C-terminal end of the PB1F2 protein (McAuley et al.,
2010).
PB1F2 with the N66S mutation has also been associated with
a delay in induction of the IFN response, which causes delayed
innate immune response (Conenello et al., 2007, 2011; Varga et al.,
2011). IFN antagonist activity was demonstrated with the PR8 H1N1
strain with both in in vitro and in vivo experiments. PB1F2 interferes
with the RIG-I/MAVs protein complex and thus inhibits the activa-
tion of the IFN regulatory factor 3, which is a downstream molecule
of the RIG-I/MAVs protein complex (Dudek et al., 2011). In contrast,
another study found that wild-type WSN inﬂuenza A virus with full
length PB1F2 protein exacerbated the expression of IFN-b through
the activation of the NF-kB pathway (Le Gofﬁc et al., 2010).This
particular hypothesis was further conﬁrmed in an in vivo study
wherein the PB1F2 protein signiﬁcantly increased the inﬂammatory
response by recruiting massive numbers of leukocytes into the air
space of mice lungs (Le Gofﬁc et al., 2011). Increased IFNg levels in
the mice repressed the innate immune response of the host against
both the virus and invading bacteria, which in turn led an oppor-
tunistic infection (Le Gofﬁc et al., 2011). L62, R75, R79, and L82 are
the amino acid residues that constitute the proinﬂammatory
domain of the PB1F2 protein of the H3N2 virus A/Hong Kong/1/
1968 virus. These residues were identiﬁed as being responsible for
causing a signiﬁcant increase in morbidity and mortality in mice
and also better-supported secondary bacterial infection (Alymova
et al., 2011).
Co-localization of PB1F2 with PB1 regulates polymerase activity
Mazur et al. (2008) described a novel additional function for
PB1F2 in epithelial cells. They demonstrated that this protein
indirectly regulates polymerase activity through its interaction
with PB1. They also demonstrated that a lack of PB1F2 during
infection resulted in the altered localization of PB1 and, conse-
quently, decreased viral polymerase activity, which in turn
produced a smaller plaque phenotype (Mazur et al., 2008).
The authors examined the PR8 strain and suggested that the
co-localization of PB1F2 with PB1 most likely leads to retention of
PB1 in the nucleus in the late phase of replication, which in turn
leads to enhanced polymerase activity. They suggested that the
C-terminal end of the PB1F2 protein is required for the
co-localization of the protein with PB1, which was conﬁrmed by
McAuley et al. (2010). McAuley et al. (2010) extended the work of
Mazur et al. (2008) and carried out studies on other strains,
including A/Brevig Mission/1/18 (H1N1; 1918 PB1F2), A/Beijing/
11/56(H1N1; Beij PB1F2), which has a truncated C-terminal end,
and A/Vietnam/1203/04 (H5N1) and A/Wuhan/359/95. (H3N2).
Kosˇı´k et al. (2011) also demonstrated that PB1F2 co-localizes with
PB1 and enhances the polymerase activity. However, they pro-
vided evidence that the N-terminal portion of the PB1F2 was
responsible for this effect, which is in contrast to results of the
aforementioned researchers. Kosˇı´k et al. (2011) also suggested
that apart from the increase in PB1 expression, there was also an
increase in the expression of other viral protein, such as NP, M1,
and NS1, in the presence of the PB1F2 protein.
Role of PB1F2 in enhancing secondary bacterial infection
The major cause of deaths in the patients infected with IAV
is not virus infection per se but secondary bacterial infections(McCullers, 2006). The major pathogens responsible for the
secondary infections are S. pneumoniae, Staphylococcus aureus,
and Haemophilus inﬂuenzae (Sethi, 2002). IAV infection causes loss
of ciliated mucus-secreting epithelial cells that line the lungs.
This results in decreased mucous production and impaired
clearance of microorganisms, as mucous is among the agents
responsible for the ﬁrst line of non-speciﬁc immune defense
against any foreign body. Due to this, an opportunistic bacteria
can reside longer in the lungs and cause secondary bacterial
infection. PB1F2 also has been implicated in enhancing secondary
pulmonary infection. It has been shown that PB1F2 causes cell
death speciﬁcally in the alveolar macrophages present in the
lungs. This elimination causes an increase in virulence by redu-
cing antigen presentation and initial viral clearance and also by
preventing crosstalk between the alveolar macrophages and
CD4þ Th cells. In the absence of the alveolar macrophages, the
antigen presentation to the CD4þ Th cells is hampered, and
consequently, its clonal expansion and its downstream effector
functions, such as cytotoxic T lymphocyte (CTL) activation, anti-
body production and inﬂammation, are impaired (Coleman,
2007). McAuley et al. (2007) demonstrated in mice that PB1F2
exacerbates inﬂammation during primary viral infection and also
has the ability to increase the frequency and severity of the
secondary bacterial infection. The observed cellular reaction in
their experiments included increased inﬂammatory inﬁltration,
epithelial cell hypertrophy, necrosis and ﬁbrin deposition. They
attributed this effect to the C-terminal region of the PB1F2 protein
(McAuley et al., 2007).Summary and conclusions
PB1F2 is a non-structural accessory protein of inﬂuenza A
viruses. Full-length PB1F2 protein is 87 to 101 amino acids long
and encoded by an alternate þ1 open reading frame within the
PB1 gene. Translation of PB1F2 mRNA is mediated by leaky
ribosomal scanning. The viral mRNA has a short half-life and is
expressed early and transiently in infected cells. The PB1F2
protein is predicted to form a positively charged amphipathic
helix and has the intrinsic property to form oligomeric structures.
Varying lengths of PB1F2 have been reported in different hosts
and subtypes of inﬂuenza A viruses. A full-length PB1F2 protein is
present in all the 20th-century pandemics strains. However, in
the recent 2009 H1N1 pandemic, the PB1F2 protein is non-
functional due to a C-terminal truncation. Hence, the signiﬁcance
of the protein in pandemic strains is unclear. PB1F2 protein is
expressed by almost all the avian inﬂuenza A strains; however,
strains from human and swine hosts have forms with premature
truncations at either the C- or N-terminal ends. It is worth noting
that most of the virus strains isolated from avian hosts and
belonging to H1N1, H2N2, H3N2 and H5N1 subtypes harbored
complete PB1F2 protein. This suggests that PB1F2 is positively
selected in these subtypes and still has not lost its function which
is contrast to the viruses from mammalian hosts.
Since the time PB1F2 was ﬁrst described by Chen et al. (2001),
many researchers have attempted to unravel its function, utility in
the life cycle and contribution towards exacerbating viral patho-
genicity. Despite many attempts, the function of the PB1F2 protein
in the life cycle of inﬂuenza virus remains unclear, as does its precise
role in virulence. Studies have shown that PB1F2 has proapoptotic
potential whereby it initiates apoptosis through the intrinsic mito-
chondrial pathway, apparently by depolarizing the MMP followed
by cytochrome c release. However, the exact mechanism by which
PB1F2 causes loss of the MMP is not yet resolved. Here, we have
discussed many reports that have describedmechanisms involved in
the depolarization of the mitochondrial membrane. These include
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or indirect modulation of the mitochondrial transport proteins, such
as ANT3 and VDAC1. Apart from the unresolved mechanism
involved in bringing about apoptosis, there is also ambiguity about
the proapoptotic ability of the protein in many inﬂuenza A strains. It
has been reported that the apoptotic function of PB1F2 is viral
strain- and cell-type-speciﬁc. It would be very interesting to study
the apoptotic potential of the PB1F2 protein in various inﬂuenza A
stains. Further studies are also warranted to determine the mechan-
ism of the interaction of the PB1F2 protein with various molecules
implicated in apoptosis.
Apart from inducing apoptosis, PB1F2 has been implicated in
possessing proinﬂammatory properties and the ability to exacerbate
viral pathogenicity. PB1F2 has been found to be pathogenic in mice,
swine and ducks, causing cellularity of the lungs and the inﬂux of
white blood cells, including T cells, dendritic cells, macrophages and
neutrophils. There is ambiguity about the antagonistic or agonistic
role of PB1F2 in regulating the IFN response. PB1F2 can also enhance
viral polymerase activity. PB1F2 facilitates secondary infection with
S. pneumonia, highlighting the complex contribution of PB1F2 in
virulence. Interestingly, very recently, it has been hypothesized that
the two functions of the PB1F2 protein, apoptosis and MAVS-
dependent IFN antagonism, converge at the level of the MAVS
protein. This crosstalk between the two cellular processes in the
mitochondria may improve our understanding of the PB1F2 protein,
which is deﬁnitely lacking in this present context (Varga and Palese,
2011).
Currently most of the research on inﬂuenza is carried out in
genetically engineered viruses. In order to generate viruses lacking
PB1F2 protein, its initiation codon is usually ablated. It has been
recently shown that this ablation causes an increase in the
expression level of the downstream protein N40. The over expres-
sion of N40 protein in turn has detrimental effect on the replication
of the virus both in vitro and in vivo experiments (Tauber et al.,
2012). Therefore, researcher should take utmost care in carrying
out studies and interpreting the existing data on genetically
engineered viruses deﬁcient in PB1F2 protein. Key questions that
are still unanswered regarding the PB1F2 protein are (i) the
functional utility in different host, (ii) the effect of C- and
N-terminal truncations, (iii) the apoptotic ability in various strains,
(iv) the precise mechanism for inducing apoptosis, (v) the patho-
genic ability in a greater range of hosts, (vi) the antagonistic or
agonistic role in modulating the innate immune response and
(vii) the correlation between sequence variability and virulence.
Thus, we believe the precise function of the PB1F2 protein remains
unclear, and there remains much to learn in this particular area.
However, research on this particular protein indicates that the
PB1F2 protein has strain-speciﬁc functions that could vary in
different hosts. The effects of the protein on the host might range
from being minimal to deleterious, either by increasing the number
and level of expression of activated genes linked to cell death or
intensifying the activity of genes causing uncontrolled inﬂamma-
tion or deregulating the innate immune responses of the host.Acknowledgments
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